PD-1 / PDCD1 Recombinant Protein Cat. No.: 11-403

Availability: In stock

$0.00

 Price Options

$0.00
psi-iconSpecifications
SPECIES:Human
SOURCE SPECIES:HEK293 cells
SEQUENCE:Leu 25 - Gln 167
FUSION TAG:Mouse IgG Fc Tag
TESTED APPLICATIONS:ELISA, WB
APPLICATIONS:This protein carries a mouse IgG2a Fc tag at the C-terminus. The protein has a calculated MW of 42.5 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
psi-iconProperties
PURITY:>95% as determined by SDS-PAGE.
PREDICTED MOLECULAR WEIGHT:42.5 kDa
PHYSICAL STATE:Lyophilized
BUFFER:PBS, pH7.4
STORAGE CONDITIONS:Lyophilized Protein should be stored at -20˚C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20˚C or -70˚C. Avoid repeated freeze-thaw cycles.
psi-iconAdditional Info
ALTERNATE NAMES:PDCD1,PD1,CD279,SLEB2
ACCESSION NO.:NP_005009.2
OFFICIAL SYMBOL:PDCD1
GENE ID:5133
psi-iconBackground and References
BACKGROUND:Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
REFERENCES:1) Ishida Y., et al., 1992, EMBO J. 11 (11): 3887–95.
2) Blank C., et al., 2007, Cancer Immunol. Immunother. 56 (5): 739–45.
3) Agata Y., et al., 1996, Int. Immunol. 8 (5): 765–72.
4) Freeman GJ., et al., 2000, J. Exp. Med. 192 (7): 1027–34.

FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.